New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

STEVENAGE, England, March 20, 2023 /PRNewswire/ — New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA** may have a dual…